Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Ermium Therapeutics logo — Controlling auto-immune diseases

Ermium Therapeutics

Controlling auto-immune diseases

Founded 2019 France France 1 employees Series A Total: $12.30M Biotechnology, Health Care +1

General Information

Company Name Ermium Therapeutics
Founded Year 2019
Location France France
Employees 1
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Ermium Therapeutics. To contact Ermium Therapeutics, visit ermium.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ermium Therapeutics compare?

A PDF of Ermium Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ermium Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ermium Therapeutics

Ermium Therapeutics, founded in 2019, is a discovery stage Biotechnology company headquartered in France. The company is focused on developing innovative therapies to tackle auto-immune diseases, as highlighted by its slogan, "Controlling auto-immune diseases." Its operations span critical industries such as Health Care and Pharmaceuticals.

In its journey towards creating impactful solutions, Ermium Therapeutics secured a €6.00M Series A investment on 30 June 2022. This investment round was supported by prominent investors, including Kurma Partners and Fountain Healthcare Partners. Such backing from reputable investors demonstrates confidence in the company's potential and its promising approach to medical innovation.

For prospective investors, Ermium Therapeutics presents an exciting opportunity at the intersection of cutting-edge biotech and urgent healthcare needs, with its focus on auto-immune diseases providing a significant addressable market.

Business keywords: auto-immune diseases, innovative therapies, CXCR4, inflammation regulation, drug discovery, intellectual property, academic collaboration, technology licensing, biopharmaceuticals, innovation award, early-stage company, therapeutic development

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €6.00M 2
Kurma Partners Fountain Healthcare Partners
Kurma Partners, Fountain Healthcare Partners
30 Jun 2022
Venture Round Undisclosed 1
Euazeo
Euazeo
01 Sep 2020
Series A €6.30M 4
IDInvest Partners Kurma Partners Erganeo
IDInvest Partners, Kurma Partners +2
12 Sep 2019

Ermium Therapeutics Alternatives & Competitors

View All Alternatives
Ermium Therapeutics vs
Ahammune Biosciences Pvt. Ltd.
Ahammune Biosciences Pvt. Ltd. India

Innovation-led drug discovery company focused on developing drugs targeting skin immune system.

Seed
9 employees
Biotechnology, Health Care
Ermium Therapeutics vs
Georgiamune Inc.
Georgiamune Inc. United States

Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fight diseas...

Series A
30 employees
Biotechnology, Health Care
Compare Ermium Therapeutics vs Georgiamune Inc.
Ermium Therapeutics vs
Asylia Therapeutics
Asylia Therapeutics

Innovative therapies reshaping immune responses against autoimmune, cancer, and infectious diseases.

Series A
1 employees
Biotechnology, Health Care
View all alternatives

FAQ About Ermium Therapeutics

Controlling auto-immune diseases
Ermium Therapeutics was founded in 2019.
Ermium Therapeutics is headquartered in France.
Ermium Therapeutics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on auto-immune diseases, innovative therapies, CXCR4 and inflammation regulation.
Ermium Therapeutics has approximately 1 employees.
Ermium Therapeutics has completed 3 funding rounds, raising a total of $12.30M. The latest funding stage is Series A.
Top alternatives and competitors to Ermium Therapeutics include Ahammune Biosciences Pvt. Ltd., Georgiamune Inc., Asylia Therapeutics, Nuvig Therapeutics Inc., COUR Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ermium Therapeutics and Ahammune Biosciences Pvt. Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ermium Therapeutics, https://bouncewatch.com/company/ermium-therapeutics, updated 31 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout